A citation-based method for searching scientific literature

Ronald de Wit, Johann de Bono, Cora N Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean-Christophe Eymard, Aristotelis Bamias, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Ásgerður Sverrisdóttir, Christine Theodore, Susan Feyerabend, Carole Helissey, Ayse Ozatilgan, Christine Geffriaud-Ricouard, Daniel Castellano. N Engl J Med 2019
Times Cited: 218







List of co-cited articles
620 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
564
46

Enzalutamide in metastatic prostate cancer before chemotherapy.
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury,[...]. N Engl J Med 2014
43

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Johann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocak, Gwenaëlle Gravis, Istvan Bodrogi, Mary J Mackenzie, Liji Shen,[...]. Lancet 2010
43

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Ian F Tannock, Ronald de Wit, William R Berry, Jozsef Horti, Anna Pluzanska, Kim N Chi, Stephane Oudard, Christine Théodore, Nicholas D James, Ingela Turesson,[...]. N Engl J Med 2004
41

Increased survival with enzalutamide in prostate cancer after chemotherapy.
Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore,[...]. N Engl J Med 2012
39

Alpha emitter radium-223 and survival in metastatic prostate cancer.
C Parker, S Nilsson, D Heinrich, S I Helle, J M O'Sullivan, S D Fosså, A Chodacki, P Wiechno, J Logue, M Seke,[...]. N Engl J Med 2013
32

Abiraterone in metastatic prostate cancer without previous chemotherapy.
Charles J Ryan, Matthew R Smith, Johann S de Bono, Arturo Molina, Christopher J Logothetis, Paul de Souza, Karim Fizazi, Paul Mainwaring, Josep M Piulats, Siobhan Ng,[...]. N Engl J Med 2013
30

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, Daygen L Finch, Conrad Oja, Joanna Vergidis, Muhammad Zulfiqar, Katherine Sunderland, Arun A Azad, Christian K Kollmannsberger,[...]. Lancet Oncol 2019
133
29

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Charles J Ryan, Matthew R Smith, Karim Fizazi, Fred Saad, Peter F A Mulders, Cora N Sternberg, Kurt Miller, Christopher J Logothetis, Neal D Shore, Eric J Small,[...]. Lancet Oncol 2015
796
29

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Christopher J Sweeney, Yu-Hui Chen, Michael Carducci, Glenn Liu, David F Jarrard, Mario Eisenberger, Yu-Ning Wong, Noah Hahn, Manish Kohli, Matthew M Cooney,[...]. N Engl J Med 2015
29

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Ian D Davis, Andrew J Martin, Martin R Stockler, Stephen Begbie, Kim N Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E Hague, Lisa G Horvath,[...]. N Engl J Med 2019
492
27

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris A Hadaschik, Julie N Graff, David Olmos, Paul N Mainwaring, Ji Youl Lee, Hiroji Uemura,[...]. N Engl J Med 2018
598
26

Abiraterone and increased survival in metastatic prostate cancer.
Johann S de Bono, Christopher J Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N Chi, Robert J Jones, Oscar B Goodman, Fred Saad,[...]. N Engl J Med 2011
26

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, Alfredo Rodriguez-Antolin, Boris Y Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe,[...]. N Engl J Med 2017
24

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Andrew J Armstrong, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Neal D Shore,[...]. J Clin Oncol 2019
304
24

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Karim Fizazi, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss,[...]. N Engl J Med 2019
355
24

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Maha Hussain, Karim Fizazi, Fred Saad, Per Rathenborg, Neal Shore, Ubirajara Ferreira, Petro Ivashchenko, Eren Demirhan, Katharina Modelska, De Phung,[...]. N Engl J Med 2018
499
24

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Kim N Chi, Neeraj Agarwal, Anders Bjartell, Byung Ha Chung, Andrea J Pereira de Santana Gomes, Robert Given, Álvaro Juárez Soto, Axel S Merseburger, Mustafa Özgüroğlu, Hirotsugu Uemura,[...]. N Engl J Med 2019
458
23

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Nicholas D James, Matthew R Sydes, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Melissa R Spears, Alastair W S Ritchie, Christopher C Parker, J Martin Russell, Gerhardt Attard,[...]. Lancet 2016
23

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Joaquin Mateo, Nuria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese,[...]. Lancet Oncol 2020
247
22

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Wassim Abida, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H Bryce, Ray McDermott, Brieuc Sautois, Nicholas J Vogelzang, Richard M Bambury, Eric Voog,[...]. J Clin Oncol 2020
170
22

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Maha Hussain, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
162
22

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Howard I Scher, Michael J Morris, Walter M Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S Antonarakis, Tomasz M Beer, Michael A Carducci, Kim N Chi,[...]. J Clin Oncol 2016
674
21

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Karim Fizazi, Howard I Scher, Arturo Molina, Christopher J Logothetis, Kim N Chi, Robert J Jones, John N Staffurth, Scott North, Nicholas J Vogelzang, Fred Saad,[...]. Lancet Oncol 2012
907
21

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
21

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.
Gerhardt Attard, Michael Borre, Howard Gurney, Yohann Loriot, Corina Andresen-Daniil, Ranjith Kalleda, Trinh Pham, Mary-Ellen Taplin. J Clin Oncol 2018
90
22

Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
20

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Nicholas D James, Johann S de Bono, Melissa R Spears, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Alastair W S Ritchie, Claire L Amos, Clare Gilson, Rob J Jones,[...]. N Engl J Med 2017
862
19

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims,[...]. N Engl J Med 2010
19

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Wassim Abida, Michael L Cheng, Joshua Armenia, Sumit Middha, Karen A Autio, Hebert Alberto Vargas, Dana Rathkopf, Michael J Morris, Daniel C Danila, Susan F Slovin,[...]. JAMA Oncol 2019
259
17

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Wassim Abida, David Campbell, Akash Patnaik, Jeremy D Shapiro, Brieuc Sautois, Nicholas J Vogelzang, Eric G Voog, Alan H Bryce, Ray McDermott, Francesco Ricci,[...]. Clin Cancer Res 2020
144
17

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
Colin C Pritchard, Joaquin Mateo, Michael F Walsh, Navonil De Sarkar, Wassim Abida, Himisha Beltran, Andrea Garofalo, Roman Gulati, Suzanne Carreira, Rosalind Eeles,[...]. N Engl J Med 2016
790
17

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Stéphane Oudard, Karim Fizazi, Lisa Sengeløv, Gedske Daugaard, Fred Saad, Steinbjørn Hansen, Marie Hjälm-Eriksson, Jacek Jassem, Antoine Thiery-Vuillemin, Orazio Caffo,[...]. J Clin Oncol 2017
164
16

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Howard I Scher, Susan Halabi, Ian Tannock, Michael Morris, Cora N Sternberg, Michael A Carducci, Mario A Eisenberger, Celestia Higano, Glenn J Bubley, Robert Dreicer,[...]. J Clin Oncol 2008
16

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Emmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J Hoimes, Ulka Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko,[...]. J Clin Oncol 2020
229
16

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
Mario Eisenberger, Anne-Claire Hardy-Bessard, Choung Soo Kim, Lajos Géczi, Daniel Ford, Loïc Mourey, Joan Carles, Phillip Parente, Albert Font, Gabriel Kacso,[...]. J Clin Oncol 2017
138
15

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Christos E Kyriakopoulos, Yu-Hui Chen, Michael A Carducci, Glenn Liu, David F Jarrard, Noah M Hahn, Daniel H Shevrin, Robert Dreicer, Maha Hussain, Mario Eisenberger,[...]. J Clin Oncol 2018
363
15

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Daniel P Petrylak, Catherine M Tangen, Maha H A Hussain, Primo N Lara, Jeffrey A Jones, Mary Ellen Taplin, Patrick A Burch, Donna Berry, Carol Moinpour, Manish Kohli,[...]. N Engl J Med 2004
15

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Matthew Smith, Chris Parker, Fred Saad, Kurt Miller, Bertrand Tombal, Quan Sing Ng, Martin Boegemann, Vsevolod Matveev, Josep Maria Piulats, Luis Eduardo Zucca,[...]. Lancet Oncol 2019
160
14

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
C Parker, E Castro, K Fizazi, A Heidenreich, P Ost, G Procopio, B Tombal, S Gillessen. Ann Oncol 2020
161
14

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
Tomasz M Beer, Andrew J Armstrong, Dana Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Christopher P Evans, Choung-Soo Kim, Go Kimura,[...]. Eur Urol 2017
196
13

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Emmanuel S Antonarakis, Changxue Lu, Hao Wang, Brandon Luber, Mary Nakazawa, Jeffrey C Roeser, Yan Chen, Tabrez A Mohammad, Yidong Chen, Helen L Fedor,[...]. N Engl J Med 2014
13

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Cora N Sternberg, Karim Fizazi, Fred Saad, Neal D Shore, Ugo De Giorgi, David F Penson, Ubirajara Ferreira, Eleni Efstathiou, Katarzyna Madziarska, Michael P Kolinsky,[...]. N Engl J Med 2020
112
13

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Elena Castro, Nuria Romero-Laorden, Angela Del Pozo, Rebeca Lozano, Ana Medina, Javier Puente, Josep Maria Piulats, David Lorente, Maria Isabel Saez, Rafael Morales-Barrera,[...]. J Clin Oncol 2019
145
13

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Oliver Sartor, Johann de Bono, Kim N Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T Tagawa, Luke T Nordquist, Nitin Vaishampayan, Ghassan El-Haddad,[...]. N Engl J Med 2021
185
13

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Noel Clarke, Pawel Wiechno, Boris Alekseev, Nuria Sala, Robert Jones, Ivo Kocak, Vincenzo Emanuele Chiuri, Jacek Jassem, Aude Fléchon, Charles Redfern,[...]. Lancet Oncol 2018
167
12

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Andrew J Armstrong, Susan Halabi, Jun Luo, David M Nanus, Paraskevi Giannakakou, Russell Z Szmulewitz, Daniel C Danila, Patrick Healy, Monika Anand, Colin J Rothwell,[...]. J Clin Oncol 2019
171
11

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, Sinja Taavitsainen, Kevin Beja, Evan W Warner, Katherine Sunderland, Christian Kollmannsberger, Bernhard J Eigl, Daygen Finch,[...]. Cancer Discov 2018
246
11

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gwenaelle Gravis, Karim Fizazi, Florence Joly, Stéphane Oudard, Franck Priou, Benjamin Esterni, Igor Latorzeff, Remy Delva, Ivan Krakowski, Brigitte Laguerre,[...]. Lancet Oncol 2013
410
11

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.